SCHEMBL4632890

SCHEMBL4632890

O=C1c2ccccc2C(=O)N1CC#CCCl

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
CASP3 P42574 2/20 0.44
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
GLS O94925 1/20 0.44
DRD3 P35462 1/20 0.43
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
MEN1 O00255 1/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9698514 0.81 ALDH1A1 (0.49) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL10851246 0.81 ALDH1A1 (0.52) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL6357561 0.81 DRD3 (0.51) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL1862779 0.81 ALDH1A1 (0.49) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL20931184 0.78 ALDH1A1 (0.47) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL4578025 0.78 ALDH1A1 (0.47) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL236347 0.78 CA12 (0.54) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL11720298 0.77 ALDH1A1 (0.66) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL10422970 0.76 SMN1; SMN2 (0.48) ALDH1A1POLBGAASMN1; SMN2NPSR1
SCHEMBL946186 0.75 CASP3 (0.50) ALDH1A1CASP3CA12CA9GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076466-A1 MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS UNIVERSITE DE MONTREAL (CA) 2022-10-26 EP disclosed
CN-114845719-A Modulators of the CULLIN3 connexin kbbd 4 as anti-cancer compounds 蒙特利尔大学 2022-08-02 CN disclosed
WO-2021119834-A1 MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS UNIVERSITE DE MONTREAL (CA) 2021-06-24 WO disclosed
WO-2021119834-A1 MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS UNIVERSITE DE MONTREAL (CA) 2021-06-24 WO disclosed
US-8772277-B2 Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-07-08 US disclosed
US-20130072467-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED 2013-03-21 US disclosed
WO-2013018929-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-07 WO disclosed
EP-1546098-B1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LAB LTD (IN) 2008-05-28 EP disclosed
US-7265147-B2 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists RANBAXY LABORATORIES LIMITED (IN) 2007-09-04 US disclosed
US-20060122253-A1 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists RANBAXY LABORATORIES LIMITED (IN) 2006-06-08 US disclosed
EP-0625978-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1994-11-30 EP disclosed
US-5308837-A 5'-amine substituted adenosine analogs as immunosuppressants MERRELL DOW PHARMACEUTICALS INC. (US) 1994-05-03 US disclosed
WO-1993016073-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1993-08-19 WO disclosed
EP-0472181-A2 5-Amine substituted adenosine analogs as immunosuppressants MERRELL PHARMACEUTICALS INC. (US) 1992-02-26 EP disclosed
EP-0358536-A2 Novel S-adenosyl methionine decarboxylase inhibitors MERRELL PHARMACEUTICALS INC. (US) 1990-03-14 EP disclosed
EP-0351475-A1 S-Adenosylmethionine decarboxylase inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1990-01-24 EP disclosed
US-4657908-A Carbonyl derivatives ICI AMERICAS, INC. (US) 1987-04-14 US disclosed
EP-0059597-B1 GUANIDINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES HAVING HISTAMINE H-2 ANTAGONIST ACTIVITY IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-04-23 EP disclosed
US-4496571-A GUANIDINE DERIVATIVE ICI AMERICAS INC. (US) 1985-01-29 US disclosed
EP-0059597-A2 Guanidino-substituted heterocyclic derivatives having histamine H-2 antagonist activity IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072467-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ESRRA, ESRRB, ESR2 ALDH1A1 785/4885POLB 2402/4885GAA 3154/4885
US-20060122253-A1 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists CHRM3, CHRM5, CHRM2 ALDH1A1 738/4885POLB 3537/4885GAA 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.